FI121236B - Förfarande för att detektera lung cancer som hanför sig till exponering av asbest - Google Patents

Förfarande för att detektera lung cancer som hanför sig till exponering av asbest Download PDF

Info

Publication number
FI121236B
FI121236B FI20065032A FI20065032A FI121236B FI 121236 B FI121236 B FI 121236B FI 20065032 A FI20065032 A FI 20065032A FI 20065032 A FI20065032 A FI 20065032A FI 121236 B FI121236 B FI 121236B
Authority
FI
Finland
Prior art keywords
asbestos
lung cancer
exposure
genes
expression
Prior art date
Application number
FI20065032A
Other languages
English (en)
Finnish (fi)
Other versions
FI20065032A (sv
FI20065032A0 (sv
Inventor
Sisko Anttila
Sakari Knuutila
Jaakko Hollmen
Salla Ruosaari
Harriet Wikman-Kocher
Penny Nymark
Original Assignee
Licentia Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy filed Critical Licentia Oy
Priority to FI20065032A priority Critical patent/FI121236B/sv
Publication of FI20065032A0 publication Critical patent/FI20065032A0/sv
Priority to EP07700288A priority patent/EP1977010A4/en
Priority to JP2008550791A priority patent/JP2009523436A/ja
Priority to PCT/FI2007/050023 priority patent/WO2007082998A1/en
Priority to US12/161,003 priority patent/US20100279281A1/en
Publication of FI20065032A publication Critical patent/FI20065032A/sv
Application granted granted Critical
Publication of FI121236B publication Critical patent/FI121236B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (13)

1. Forfarande för att identifiera lungcancer som hän för sig tili utsättning för asbest, kännetecknat därav att vid förfarandet detekteras obalans av alleler (AI) i ett frän en 5 lungeancerpatient härstammande lungcancercellprov i det kromosomala omrädet 19p 13.3-pl3.1 av lungcancerceller och eventuellt i minst ett av följande kromosomala tilläggsomräden av lungcancerceller: a) 9q32-34.3; 10 b) 2p21 -p 16.3; c) 16p 13.3; och d) 22ql2.3-ql3.1.
2. Förfarande enligt patentkrav 1, varvid närvaron av AI i omrädet 19pl3.3-p 13.1 bevisar 15 att maligniteten av lungcancercellen har samband med utsättning för asbest.
3. Förfarande enligt patentkrav 2, varvid närvaron av AI ytterligare i minst ett av de nämnda tilläggsomrädena bekräftar att maligniteten av lungcancercellen har samband med utsättning för asbest. 20
4. Förfarande enligt patentkrav 1, varvid det kromosomala tilläggsomrädet är 9q33.1.
5. Förfarande enligt patentkrav 1, varvid det kromosomala tilläggsomrädet är 2p21-pl6.3. 25
6. Förfarande enligt patentkrav 1, varvid närvaron av AI i det kromosomala omrädet 19p 13.3-p 13.1 bestäms genom användning av minst en av följande mikrosatellitmarkörer: 19s814, 19S883, I9S878, 19S424, 1.9S894, 19S216, 19S177, 19S1034, 19S873, 19S884, 19S916, 19S583, 19S535, 19S906, 19S221, 19S840, I9S917, 19S895 och 19S568. 30
7. Förfarande enligt patentkrav 1, varvid närvaron av AI bestäms genom heterozygotförlustanalys (LOH). 65
8. Förfarande enligt patentkrav 1, varvid närvaron av AI bestäms genom att framställä en genuttrycksprofil som omfattar uttrycksresultat av gener som ligger i det kromosomala omrädet 19p 13.3-p 13.1. 5
9. Förfarande enligt patentkrav 7, varvid genuttrycksprofilen omfattar uttrycksresultat av minsl en i tabell 5 listad gen, vilka gener utväljs frän gruppen: FBXL12, PRKACA, SIRT6 och PRKCvSI-I.
10 10. Förfarande enligt patentkrav 1, varvid närvaron av AI bestäms genom användning av fluorescerande in situ-hybridiseringsteknologi (FISH).
11. Förfarande enligt patentkrav 1, varvid lungcancerprovet som skall undersökas har erhällits genom lasermikrodissektionsteknologi. 15
12. Förfarande enligt patentkrav 1, varvid det kromosomala tilläggsomrädet är 9q32-34.3.
13. Användning av en reagensförpackning vid detektering av lungcancer som hänför sig tili asbest, kännetecknad därav att reagensförpackningen omfattar medel för att 20 genomföra ett förfarande enligt patentkrav 1.
FI20065032A 2006-01-18 2006-01-18 Förfarande för att detektera lung cancer som hanför sig till exponering av asbest FI121236B (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI20065032A FI121236B (sv) 2006-01-18 2006-01-18 Förfarande för att detektera lung cancer som hanför sig till exponering av asbest
EP07700288A EP1977010A4 (en) 2006-01-18 2007-01-18 METHOD FOR IDENTIFYING LUNG CANCERS ASSOCIATED WITH ASBESTOS EXPOSURE
JP2008550791A JP2009523436A (ja) 2006-01-18 2007-01-18 アスベスト被曝に関連した肺癌を同定する方法
PCT/FI2007/050023 WO2007082998A1 (en) 2006-01-18 2007-01-18 Method of identifying lung cancers associated with asbestos-exposure
US12/161,003 US20100279281A1 (en) 2006-01-18 2007-01-18 Method of identifying lung cancers associated with asbestos-exposure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20065032 2006-01-18
FI20065032A FI121236B (sv) 2006-01-18 2006-01-18 Förfarande för att detektera lung cancer som hanför sig till exponering av asbest

Publications (3)

Publication Number Publication Date
FI20065032A0 FI20065032A0 (sv) 2006-01-18
FI20065032A FI20065032A (sv) 2007-07-19
FI121236B true FI121236B (sv) 2010-08-31

Family

ID=35883930

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20065032A FI121236B (sv) 2006-01-18 2006-01-18 Förfarande för att detektera lung cancer som hanför sig till exponering av asbest

Country Status (5)

Country Link
US (1) US20100279281A1 (sv)
EP (1) EP1977010A4 (sv)
JP (1) JP2009523436A (sv)
FI (1) FI121236B (sv)
WO (1) WO2007082998A1 (sv)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670314A (en) * 1994-02-22 1997-09-23 Regents Of The University Of California Genetic alterations that correlate with lung carcinomas
US20030054386A1 (en) * 2001-06-22 2003-03-20 Stylianos Antonarakis Method for detecting diseases caused by chromosomal imbalances
AU2002331780A1 (en) * 2001-08-31 2003-03-18 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
BRPI0410634A (pt) * 2003-05-30 2006-06-13 Astrazeneca Uk Ltd processo
EP1713938A2 (en) * 2004-02-09 2006-10-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
EP1907013A4 (en) * 2005-05-26 2009-12-23 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CHEMOMOMESISANT NEOPLASM

Also Published As

Publication number Publication date
JP2009523436A (ja) 2009-06-25
FI20065032A (sv) 2007-07-19
WO2007082998A1 (en) 2007-07-26
US20100279281A1 (en) 2010-11-04
EP1977010A4 (en) 2009-07-15
EP1977010A1 (en) 2008-10-08
FI20065032A0 (sv) 2006-01-18

Similar Documents

Publication Publication Date Title
US20190300963A1 (en) Mirna expression signature in the classification of thyroid tumors
Dinter et al. Molecular classification of neuroendocrine tumors of the thymus
KR101583546B1 (ko) 유전자 다형성을 이용한 소라페닙 치료에 대한 반응성 예측방법
JP4938672B2 (ja) ｐ５３の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
EP2307028B1 (en) Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
EP1824997B1 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
Nakka et al. Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma
CA2945531C (en) Mirna expression signature in the classification of thyroid tumors
KR20080065476A (ko) 폐암 환자 또는 폐암 치료를 받은 폐암 환자에 대한 폐암재발의 위험을 예측하는 방법, 폐암 환자 또는 폐암 치료를받은 환자의 폐암 재발 위험성에 대한 보고서를 작성하는방법, 그에 의하여 작성된 보고서, 폐암 환자 또는 폐암치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한조성물, 키트 및 마이크로어레이
AU2012345789A1 (en) Methods of treating breast cancer with taxane therapy
Wrage et al. Identification of HERC 5 and its potential role in NSCLC progression
WO2008112749A1 (en) Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
Davanian et al. Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature
Enomoto et al. Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non‐cancerous gastric mucosae
WO2007058623A1 (en) Methods of predicting hepatocellular carcinoma recurrence by the determination of hepatocellular carcinoma recurrence-associated molecular biomarkers
EP1836313A2 (en) Methods for assessing patients with acute myeloid leukemia
Dierlamm et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Chen et al. Genetic variants of MGMT, RHPN 2, and FAM 49A contributed to susceptibility of nonsyndromic orofacial clefts in a Chinese population
WO2022221566A1 (en) Methods and kits for identifying subjects responsive to arginine deprivation therapy
US20080003603A1 (en) Human melanoma mutation
FI121236B (sv) Förfarande för att detektera lung cancer som hanför sig till exponering av asbest
EP2630259B1 (en) Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors
EP2494067A1 (en) Method for the prognosis of ovarian carcinoma
EP3201358A1 (en) Markers of poor prognosis acute myeloid leukemias (amls) and uses thereof
WO2022015860A1 (en) Biomarkers for identifying patients at high risk of progressing from barrett's esophagus to esophageal adenocarcinoma

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121236

Country of ref document: FI

MM Patent lapsed